Literature DB >> 9671399

Concordant methylation of the ER and N33 genes in glioblastoma multiforme.

Q Li1, A Jedlicka, N Ahuja, M C Gibbons, S B Baylin, P C Burger, J P Issa.   

Abstract

Methylation of promoter-associated CpG islands appears to be a potential way by which tumor suppressor genes are inactivated in cancer. Using Southern blot analysis, we have studied the methylation of several genes in glioblastoma multiforme (GBM), trying to determine their contribution to tumorigenesis. Genes studied included the estrogen receptor (ER), N33, the candidate tumor-suppressors P15, P16 and HIC1 and a control gene, c-abl. Hypermethylation of N33, ER, HIC1, P16, P15 and c-abl were found in 61%, 59%, 60%, 5%, 2% and 0% of GBM respectively. HIC1 methylation was detected in normal brain as well, but appeared to be more extensive in tumors. ER and N33 methylation were significantly more frequent in tumors from individuals over the age of 40 (70% and 88% vs 36% and 14%). In addition, there was a strong association between ER and N33 methylation, which were concordant in 81% of the cases (P<0.01). ER and N33 methylation in GBM may therefore appear as a result of shared etiologic factors, which may relate in part to aging cell populations in the brain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671399     DOI: 10.1038/sj.onc.1201831

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

Review 1.  TUSC3: functional duality of a cancer gene.

Authors:  Kateřina Vašíčková; Peter Horak; Petr Vaňhara
Journal:  Cell Mol Life Sci       Date:  2017-09-19       Impact factor: 9.261

2.  CpG island methylator phenotype in colorectal cancer.

Authors:  M Toyota; N Ahuja; M Ohe-Toyota; J G Herman; S B Baylin; J P Issa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

Review 3.  Methylation matters.

Authors:  J F Costello; C Plass
Journal:  J Med Genet       Date:  2001-05       Impact factor: 6.318

4.  Predicting relapse in favorable histology Wilms tumor using gene expression analysis: a report from the Renal Tumor Committee of the Children's Oncology Group.

Authors:  Chiang-Ching Huang; Samantha Gadd; Norman Breslow; Colleen Cutcliffe; Simone T Sredni; Irene B Helenowski; Jeffrey S Dome; Paul E Grundy; Daniel M Green; Michael K Fritsch; Elizabeth J Perlman
Journal:  Clin Cancer Res       Date:  2009-02-10       Impact factor: 12.531

Review 5.  Epigenetic changes in gliomas.

Authors:  Rebecca Burgess; Robert Jenkins; Zhiguo Zhang
Journal:  Cancer Biol Ther       Date:  2008-09-18       Impact factor: 4.742

6.  Promoter Methylation of RASSF1A Associates to Adult Secondary Glioblastomas and Pediatric Glioblastomas.

Authors:  Jorge Muñoz; María Del Mar Inda; Paula Lázcoz; Idoya Zazpe; Xing Fan; Jorge Alfaro; Teresa Tuñón; Juan A Rey; Javier S Castresana
Journal:  ISRN Neurol       Date:  2012-01-09

7.  Expression of the Hypermethylated in Cancer gene (HIC-1) is associated with good outcome in human breast cancer.

Authors:  G Nicoll; D N Crichton; H E McDowell; N Kernohan; T R Hupp; A M Thompson
Journal:  Br J Cancer       Date:  2001-12-14       Impact factor: 7.640

8.  Distribution of estrogen and progesterone receptors isoforms in endometrial cancer.

Authors:  Hila Kreizman-Shefer; Jana Pricop; Shlomit Goldman; Irit Elmalah; Eliezer Shalev
Journal:  Diagn Pathol       Date:  2014-03-31       Impact factor: 2.644

9.  Digital transcriptome profiling of normal and glioblastoma-derived neural stem cells identifies genes associated with patient survival.

Authors:  Pär G Engström; Diva Tommei; Stefan H Stricker; Christine Ender; Steven M Pollard; Paul Bertone
Journal:  Genome Med       Date:  2012-10-09       Impact factor: 11.117

10.  Epigenetic Alteration by DNA Promoter Hypermethylation of Genes Related to Transforming Growth Factor-β (TGF-β) Signaling in Cancer.

Authors:  Sann Sanda Khin; Riko Kitazawa; Takeshi Kondo; Yuka Idei; Masayo Fujimoto; Ryuma Haraguchi; Kiyoshi Mori; Sohei Kitazawa
Journal:  Cancers (Basel)       Date:  2011-03-03       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.